Document:

EX-10.12

 Exhibit 10.12 

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (“Agreement”) is made and entered into on February 25, 2021 by and between Evan G. Dick, PhD
(“Consultant”), and Context Therapeutics LLC, a Delaware limited liability company (“Company”). 

BACKGROUND 
 Company and
Consultant desire to enter into this Agreement whereby the Consultant shall perform certain services for the Company, as more specifically set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the parties agree as follows: 

1. Services to be Performed by Consultant. 

(a) During the term of this Agreement, Consultant shall perform for the Company such services as are agreed to in writing by and between the
parties and which shall be described and attached as Exhibit A, which is incorporated to and part of this Agreement (the “Services”). 

(b) Consultant shall perform all services and duties contemplated hereunder pursuant to any time schedule for such services and in such form
as set forth on Exhibit A or as otherwise agreed to by the parties. Consultant shall make every effort to schedule his hours of service to the Company consistently with the needs of the Company so as to be coordinated with other scheduling
obligations of the parties. 
 (c) Consultant shall comply with all laws and regulations applicable to providing the Services and Consultant
shall pay for all licenses, permits and approvals necessary for Consultant to provide the Services. 
 2. Compensation. 

(a) Compensation for Services. As compensation for Consultant’s performance of the Services, the Company shall pay Consultant as
set forth on Exhibit A within thirty days after the Company’s receipt from Consultant of appropriate documentation. 
 (b) Out-of-Pocket Expenses. Company shall reimburse Consultant for all of Consultant’s reasonable
out-of-pocket travel and meal expenses reasonably incurred by Consultant with respect to the Services within thirty (30) days after the Company’s receipt of
appropriate documentation from Consultant of such expenses. 
 (c) Invoicing. Consultant shall send the Company monthly invoices for
all amounts payable under this Agreement. Each invoice submitted by Consultant shall be accompanied by any documentation that the Company may reasonably request, including receipts for
out-of-pocket expenses. Each such invoice shall specify (i) the time period covered by the invoice, (i) describe in reasonable detail the Services or expenses
for which payment is sought, and (iii) such other detail as may be reasonably requested by the Company. 
 Certain
identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been omitted. 

 3. Independent Contractor Status. 

(a) Independence. Consultant shall have no authority to contract for or obligate the Company in any way. In performance of his
obligations, it is understood that Consultant shall be, at all times and for all purposes, acting and performing as an independent contractor and not as an employee, agent or servant of the Company. Nothing in this Agreement shall be construed to
create a joint venture, partnership, association, or other affiliation or like relationship between the parties, it being specifically agreed that the relationship is and shall remain that of independent parties to a contractual relationship as set
forth in this Agreement. Each party shall comply with and be solely responsible for his or its own compliance with all pertinent laws and regulations governing the activities performed by them. Consultant is retained by the Company only for the
purposes and to the extent set forth in this Agreement and Consultant’s relation to the Company shall, during the period of this Agreement, be one of total independence, except as limited by this Agreement, and Consultant, subject to
Section 6, shall be free to dispose of such portion of his entire time, energy, and skill during regular business hours as he is not obligated to devote hereunder to the Company, in such manner as it sees fit to such persons, firms,
corporations, and other entities as it deems advisable. 
 (b) Federal, State and Local Taxes. Consultant agrees that it shall be
responsible for the payment of all taxes, estimated or otherwise, federal, state, and local, and pay such taxes when due during the years of this Agreement. The parties agree that the Company will file information returns with all appropriate
government agencies detailing the total consideration paid to Consultant during each year that services are performed under this Agreement. To this end, Consultant shall provide the Company with its taxpayer identification number and mailing
address. Company will provide a copy to Consultant of any such information as may be required by applicable statutes or regulations. The parties agree that if any law should be enacted to require source withholding of estimated income tax
liabilities from payments to independent consultants, Consultant will execute any forms needed to implement such withholding and the Company will be permitted to withhold such funds from any payments due to Consultant as consideration under this
Agreement for purposes of paying the appropriate governmental agency. 
 4. Work Product. As used in this Agreement,
“Work Product” shall mean any designs, drawings, specifications, documentation, computer software, reports, testing procedures, inventions, discoveries and other items made or conceived by Consultant in providing the
Services. Each Work Product shall be a “work made for hire” within the meaning of the copyright laws of the United States and any similar laws of any other jurisdiction. To the extent that a Work Product does not qualify as a “work
made for hire” or that Consultant otherwise has rights in any Work Product notwithstanding the foregoing, Consultant hereby irrevocably assigns to the Company and agrees that the Company shall be the sole and exclusive owner of, all right,
title and interest in and to the Work Product, including all patent, copyright, trade secret and other proprietary rights therein that may be secured in any place under laws now or hereafter in effect. 

5. Confidentiality. 
 (a)
Confidential Information. For the purposes of this Agreement, the term “Confidential Information” means any Company information known to Consultant as a result of Consultant’s duties hereunder or that is disclosed by the
Company to Consultant in any manner 

  
 2 

 
and all tangible embodiments of such information. Confidential Information shall not include any information that (i) is or becomes publicly known through no fault of Consultant;
(ii) is developed independently by Consultant; or (iii) is rightfully obtained by Consultant from a third party who does not owe Company a duty to preserve its confidentiality. 

(b) Permitted Purposes. “Permitted Purpose” means the purpose for which the Company disclosed particular Confidential
Information to Consultant. Consultant shall use Confidential Information solely for Permitted Purposes. 
 (c) Nondisclosure
Obligation. From the time that Confidentiality Information became known to Consultant or is disclosed to Consultant until the time that such Confidential Information becomes publicly known through no fault of Consultant, Consultant shall not
disclose Confidential Information to any person other than those who are subject to a nondisclosure obligation comparable in scope to this Agreement and who have a need to know such Confidential Information for a Permitted Purpose. Notwithstanding
anything to the contrary herein, Consultant may disclose Confidential Information to the extent required by a court or other governmental authority. 

6. Term of Agreement. This agreement shall become effective on the date hereof and remain in effect for the period specified on Exhibit
A unless terminated sooner pursuant to Section 7. 
 7. Termination of the Agreement. 

(a) By Notice. This Agreement may be terminated by either party for any reason whatsoever upon at least thirty (30) days prior
written notice to the other party. 
 (b) By Company With Cause. This Agreement may be
terminated immediately by the Company upon written notice for cause. Cause under this Section 7(b) is defined as Consultant breaching any clause of this Agreement or failure to perform Consultant’s obligations under this Agreement. 

(c) By Consultant With Cause. This Agreement may be terminated immediately by Consultant upon written notice for cause. Cause under
this Section 7(c) is defined as the Company breaching any clause of this Agreement or failure to perform the Company’ s obligations under this Agreement. 

(d) Effect of Termination. Upon expiration or termination of this Agreement, neither party shall have any further obligations
hereunder; provided, however, that Sections 4, 5, 8 and 10 shall survive any termination of this Agreement. 
 8. Disclaimer of
Warranties; Limitation of Liabilities. 
 (a) EXCEPT FOR THE EXPRESS WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER COMPANY NOR
CONSULTANT MAKES ANY WARRANTIES TO THE OTHER, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ALL SUCH OTHER WARRANTIES ARE HEREBY DISCLAIMED. 

  
 3 

 (b) EXCEPT FOR EITHER PARTY’S WILLFUL MISCONDUCT, NEITHER PARTY SHALL BE LIABLE TO THE
OTHER, FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, LOST OPPORTUNITY, LOST SAVINGS OR LOSS OF GOODWILL) SUFFERED OR INCURRED IN CONNECTION WITH OBSERVATION,
PERFORMANCE, NON-OBSERVATION OR NON-PERFORMANCE UNDER THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

(c) THE ENTIRE LIABILITY OF CONSULTANT TO THE COMPANY ARISING FROM OR IN CONNECTION WITH THIS AGREEMENT OR WORK ORDER, HOWEVER CAUSED,
REGARDLESS OF THE FORM OF ACTION AND ON ANY THEORY OF LIABILITY, INCLUDING CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER TORT, SHALL BE LIMITED TO DIRECT DAMAGES NOT TO EXCEED IN THE AGGREGATE THE AMOUNT ACTUALLY PAID OR PAYABLE BY THE COMPANY TO
CONSULTANT UNDER THIS AGREEMENT FOR THE AFFECTED SERVICES. 
 9. No Assignment, Subcontract or Delegation. This agreement shall not
be assigned, subcontracted, or delegated by Consultant without written consent of the Company. 
 10. General Provisions. 

(a) Further Assurances. Each party shall, at the request of the other party, take all action necessary, and shall execute and deliver
to the requesting party such further instruments and take such other actions, as the requesting party may reasonably request, in order to carry out more effectively the arrangements contemplated by this Agreement. 

(b) Governing Law. This Agreement shall be interpreted and construed under the laws of the Commonwealth of Pennsylvania. 

(c) Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable,
the remaining provisions will nevertheless continue in full force and effect and the Agreement shall be construed in all respects as though such invalid or unenforceable provision were omitted. 

(d) Amendment. This Agreement may only be changed by written consent of both parties. 

(e) Successors. The rights and obligations of Company under this Agreement shall inure to the benefit of and be binding upon the
successors of Company and the heirs and legal representatives of Consultant. 
 (f) Headings. Headings used in this Agreement are
solely for the convenience of the parties and shall be given no effect in the construction or interpretation of this Agreement. 

  
 4 

 (g) Waiver. No waiver of any breach shall be valid or binding unless approved in
writing by the non-breaching party. Forbearance or indulgence by the non-breaching party shall not constitute a waiver of the covenant or condition to be performed by
the breaching party or of any remedy available to the non-breaching party. No waiver of any breach of this Agreement shall constitute or be deemed a waiver of any other or subsequent breach. 

(h) Changes in Law. In the event there are changes to or clarifications of federal, state or local statutes, regulations, or rules
which would materially affect the operation of Company, the parties agree to examine this Agreement and to renegotiate any applicable provisions to accommodate the changes in law. 

(i) Counterparts. This Agreement may be executed in one or more counterparts, all of which together shall constitute only one
Agreement. 
 (j) Notice. Any notice required to be given pursuant to this Agreement shall be in writing and shall be deemed to have
been given when delivered in person, by courier, or by registered, certified mail or when sent by telecopier (with receipt confirmed). Such notice or communication shall be addressed as follows: 

If to Company, to: 
 Context
Therapeutics LLC 
 3675 Market St, Ste 200 

Philadelphia, PA 19104 

Attention: Martin Lehr, CEO 

[***] 
 If to the
Consultant, to: 
 Evan G. Dick, PhD 

[***] 
 [***] 

[***] 
 [***] 

(k) Complete Agreement. This Agreement constitutes the complete understanding of the parties and supersedes any and all other
agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other
statement or promise relating to the subject matter of this Agreement which is not contained herein, shall be valid or binding. 
 [signature
page follows] 

  
 5 

 IN WITNESS WHEREOF, the parties sign and execute this Consulting Agreement intending to be
legally bound on the date set forth above. 
  

			
	CONTEXT THERAPEUTICS LLC
		
	By:	 	 /s/ Martin Lehr

 

	Name:	 	 Martin Lehr

	Title:	 	 CEO

  

			
	CONSULTANT
		
	By:	 	 /s/ Evan G. Dick, PhD

 

	Name:	 	Evan G. Dick, PhD

  
 6 

 EXHIBIT A 

Description of Services 
  

	1.	 Scope of the Services. 

Consultant shall provide research and development, and related advisory services. 
  

	2.	 Schedule of Services. 

Services will be billed on an hourly basis at a rate of $250 per hour (“Hourly Retainer”). Services capped at 80 hours per month but may be amended
based upon mutual written consent. 
 Upon a financing resulting in gross proceeds of not less than $10,000,000, Consultant’s Hourly Retainer shall be
converted automatically to a monthly retainer wherein services will be billed monthly at a rate of $20,000 per month. 
 Effective as of the Effective Date,
Consultant shall receive a restricted unit award (the “Restricted Units”) of 300,581 Units that will represent 1.0% of the Company’s fully diluted capitalization. The Restricted Units will vest in substantially equal installments of
1/24 on the last day of each of the 24 months immediately following the Effective Date, subject to Consultant’s continuous service to the Company through each such date. The Restricted Units will be subject to the terms and conditions of the
Company’s Limited Liability Company Agreement (as amended from time to time), and the form of restricted unit agreement between Consultant and the Company attached hereto as Exhibit B. 

 

	3.	 Type of Service. 

Review background information and documents and provide research and development services and advice. 

 

	4.	 Term of Agreement. 

This Agreement shall become effective as of the Effective Date of this Agreement and continue until terminated by either of the parties hereto. 

  
 7EX-10.13

 Exhibit 10.13 

BOARD OF DIRECTOR SERVICES AGREEMENT 

This BOARD OF DIRECTOR SERVICES AGREEMENT (the “Agreement”) is made and entered into effective as of this 5th day of March 2021 (the “Effective Date”), by and between Context Therapeutics LLC, a Delaware limited liability company, which is expected to be converted to a Delaware corporation
pursuant to a statutory conversion and change its name to Context Therapeutics Inc. (together, the “Company”), and                     
(“Director”). 
 WHEREAS, the Company desires to retain the services of Director for the benefit of the Company and its members or
stockholders; and 
 WHEREAS, Director desires to serve on the Company’s Board of Directors (the “Board”) for the period of
time and subject to the terms and conditions set forth herein. 
 NOW, THEREFORE, for consideration and as set forth herein, the parties
hereto, intending to be legally bound, agree as follows: 
 1. APPOINTMENT; DUTIES. The Company hereby engages Director to serve as a
member of the Board, which engagement Director accepts, in all cases subject to any required Board and/or security holder approval. During the Term (as defined below), Director will be expected to, among other things, (a) attend all meetings of
the Board and any committee thereof, to the extent Director serves on such committee(s); (b) provide guidance and advice to the Company on matters and developments potentially relevant to the Company’s business and areas of research and
development and otherwise, as the Company requests; (c) review and comment on the Company’s strategies for research and development, product definition, regulatory approvals, business development and marketing, partnering, and fund
raising, as well as its related presentations and materials; (d) provide other advice and consultation to the Company at its request, including a reasonable amount of informal consultation in person, over the telephone, by email, or otherwise
as requested by the Company, at times reasonably convenient to Director; and (e) with the Company’s approval in each instance, make introductions to individuals and entities that might be of assistance to the Company. Director shall
perform his or her duties hereunder consistent with the level of diligence customarily associated in industry with service as a non-executive, independent Board member. The Company confirms that
Director’s duties hereunder shall not regularly require Director to devote more than 10 hours of service each month; provided, however, that the parties acknowledge that there may be occasions when a greater commitment is required.
Notwithstanding anything to the contrary herein, the Company acknowledges and agrees that Director might not be able to attend every scheduled Board meeting or conference call (although he or she shall make reasonable best efforts to do so). 

2. TERM. The term of Director’s appointment and services under this Agreement will commence as of the Effective Date and will
continue for three years (the “Term”). Notwithstanding the foregoing, either Director or the Company may terminate the Term (and Director’s service on the Board) at any time, for any reason, by providing the other no less than 15
days’ prior written notice. Upon termination of the Term by either party for any reason, or upon the natural expiration of the Term, Director will resign his or her position as a director of the Company and any of its affiliates, and as a
member of all Board committees on which Director serves. 
 3. COMPENSATION. 

a. Primary Consideration. In consideration Director’s service under this Agreement, during the Term, Company shall
pay Director cash compensation in the amount of Thirty-Five Thousand Dollars ($35,000) annually, payable in equal quarterly installments and prorated in the 

  
 1 

 
event of partial year(s) of service, based on the percentage of the year served. Additionally, the Company shall grant Director a nonqualified option to purchase 90,000 shares of Context
Therapeutics Inc. (the “Option”) pursuant to and subject to the terms and conditions of the Context Therapeutics Inc. 2021 Equity Incentive Plan (the “Plan”), with an exercise price equal to the fair market value on the grant
date and with One Thirty-Sixth (1/36th) of the Option vested on the grant date, and One Thirty-Sixth (1/36th) of the Option
vesting on the last day of each month thereafter during the Term until fully vested, provided that Director continues to provide services to the Company under this Agreement as of any such vesting date. Notwithstanding anything to the contrary in
the Plan or in the stock option agreement relating to the Option, in the event of Director’s continued service to the Company in another capacity following the termination of his/her directorship pursuant to this Agreement, the exercise period
for the Director’s vested Option as of the date of termination will be extended for the period of continued service by Director to the Company in another capacity or, if earlier, until the Option’s expiration date. 

b. Additional Consideration. Should Director, during the Term, serve in the following additional roles, Director shall
receive the following additional compensation: 
  

	 	•	 	 Chair of the Board – An additional annual cash retainer of $15,000 and an additional grant of 90,000 options
pursuant to the terms of Section 3(a); 

  

	 	•	 	 Chair of the Board’s Audit Committee (if any) – An additional annual cash retainer of $15,000;

  

	 	•	 	 Chair of the Board’s Compensation Committee (if any) – An additional annual cash retainer of $10,000;

  

	 	•	 	 Chair of Board’s Nominating and Corporate Governance Committee (if any) – An additional annual cash
retainer of $7,500; 

  

	 	•	 	 Member of the Board’s Audit Committee – An additional annual cash retainer of $7,500;

  

	 	•	 	 Member of the Board’s Compensation Committee (if any) – An additional annual cash retainer of $5,000;
and 

  

	 	•	 	 Member of the Board’s Nominating and Corporate Governance Committee (if any) – An additional annual
cash retainer of $3,500. 

 In all cases, any such additional compensation shall be prorated during any
partial year(s) of service, based on the percentage of the year that Director provides such service. 
 c. Expense
Reimbursement. The Company shall reimburse Director for reasonable travel and other out-of-pocket expenses incurred by Director in connection with the
services provided by Director under this Agreement, provided that (i) Director provides receipts and other reasonable documentation as requested by the Company and (ii) Director provides a written report of his or her expenses on a
quarterly basis to the Company’s Controller or the Chair of the Company’s Compensation Committee for review. Director will also be expected to abide by any travel
and/or out-of-pocket expense guidelines that are provided to him or her by the Company. Subject to this Section 3(c), in the event Director’s air
travel plans require 

  
 2 

 
Director to take a flight over three (3) hours in duration, the Company agrees to permit reimbursement for first-class air travel for that flight, to the extent it is reasonably available
and priced. 
 4. RETURN OF PROPERTY. Upon the conclusion of the Term for any reason, or at such earlier time as the Company may
request, Director will return to the Company all Company property that is in Director’s possession or control as of the date of such conclusion, including without limitation all Confidential Information (as defined below) and any documents
related thereto; provided that, in the event of Director’s continued service to the Company in another capacity following the termination of his or her directorship pursuant to this Agreement, Director shall be permitted to retain any
such property to the extent it is necessary to fulfill Director’s obligations to the Company in such other capacity, subject to the terms and conditions governing such continued service to the Company. 

5. CONFIDENTIALITY. Director shall, at all times in the future (both during and after the Term), hold in strictest confidence and not
use or disclose, except for the benefit of the Company, any Confidential Information. “Confidential Information” means any Company proprietary or confidential information, trade secrets or know-how,
including but not limited to research, developments, technical data, processes, data techniques, prototypes, client lists and information, prospective client information, proposals, client purchasing practices, prices and pricing methodology, cost
information, terms and conditions of business relationships with clients, software, inventions, processes, formulas, technology, designs, drawings, engineering, sales and profit figures, finances, and other business information that Director learns
of or obtains during the course of his or her service to the Company, either directly or indirectly, in writing, orally or by review or inspection of documents or other tangible property. However, Confidential Information does not include any of the
foregoing items that (a) are generally available to the public, (b) have become publicly known through no wrongful act of Director, (c) is made available to the Director on a non-confidential
basis by a third party having the lawful right to do so, or (d) is required to be disclosed by order of a court of competent jurisdiction or other government authority or agency provided that the Director promptly notifies the Company of such
requirement. The obligations imposed on the parties hereunder shall continue in force for a period of five (5) years from the Effective Date. 

6. NON-SOLICITATION OF EMPLOYEES. During the Term and for one year thereafter, Director
will not cause, attempt to cause, or assist another person or entity to cause any employee of the Company to cease working for the Company or to accept an engagement or employment with another employer that is a competitor of the Company. 

7. INTELLECTUAL PROPERTY. Director shall promptly disclose and hereby transfers and assigns to the Company all right, title and
interest in and to all techniques, methods, processes, software, documents, formulae, improvements, inventions and discoveries (and any patents issuing thereon) made or conceived or reduced to practice by Director, solely or jointly with others, in
the course of performing duties as described in Section 1 herein or with the use of materials or facilities of the Company, during the Term, and all intellectual property rights related to any of the foregoing (collectively
“Inventions”). Director shall not publish any such Invention without the Company’s prior written consent. When requested by the Company, Director will make available to the Company all papers, notes, drawings, data and other
information relating to any such Inventions. Director will promptly sign any documents (including U.S. and foreign copyright, trademark and patent assignments) requested by the Company related to the above assignment of rights and such Inventions
and will cooperate with the Company at the Company’s request and expense in preparation and prosecution of any U.S. or foreign copyright, trademark or patent applications related to such rights and Inventions. Director’s obligations under
this Section 7 shall survive termination or expiration of the Term. 

  
 3 

 8. ENFORCEMENT. Director acknowledges and agrees that the Company may suffer
irreparable harm in the event that Director breaches any of Director’s obligations under Sections 4, 5, 6 or 7 of this Agreement and that monetary damages may be inadequate to compensate the Company for such breach. Accordingly, Director agrees
that, in the event of a breach by Director of any of his or her obligations under Sections 4, 5, 6 or 7 of this Agreement, the Company will be entitled to seek from any court of competent jurisdiction preliminary and permanent injunctive relief, and
expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. The Company will be entitled to seek recovery of its costs incurred in connection with any action to enforce Sections 4, 5, 6 or 7 of this
Agreement, including reasonable attorneys’ fees and expenses, to the maximum extent permitted by law. 
 9. NOTICE OF OUTSIDE
ACTIVITIES. Director acknowledges that the services to be performed for the Company hereunder are essential to the Company and, therefore, during the Term, Director will provide prior written notice to the Company of any consulting projects for
or outside employment with companies whose business is, or is actively planning to become, Directly Competitive with the business of the Company. Following its receipt of such notification, the Company may terminate this Agreement at any time
effective immediately, without further obligation, except as to fees already earned pursuant to this Agreement. “Directly Competitive” shall mean companies that engage in the research and development and/or sale of selective
antiprogrestins, Claudin 6, or Sigma1 regulators. The Company acknowledges Director’s commitments to
                                         are not
Directly Competitive to this Company. 
 10. REPRESENTATION. Director represents that he or she is not bound by any agreement,
including with any current or prior employer, that would prevent, or substantially limit, Director from providing the services described in Section 1 above. 

11. NOTIFICATION. Unless prohibited by law from doing so, Director will notify the Company promptly if he or she is subpoenaed or
otherwise served with legal process in any matter involving the Company, its affiliates or their Confidential Information. Director will notify the Company if any attorney who is not representing the Company contacts or attempts to contact Director
(other than Director’s own legal counsel) to obtain information that in any way relates to the Company or its affiliates, and Director will not discuss any of these matters with any such attorney without first so notifying the Company and
providing the Company with an opportunity to have its attorney present during any meeting or conversation with any such attorney. 
 12.
MUTUAL NON-DISPARAGEMENT. Director and the Company mutually agree to forbear from making, causing to be made, publishing, ratifying or endorsing disparaging or derogatory statements or
comments about the other, including on social media. Further, the parties hereto agree to forbear from making any public or non-confidential statement with respect to any claim or complaint against the other
party, without the consent of such other party, to be given in advance of any such statement. This Section shall not prevent either party from making statements required by applicable law or to governmental entities, or the Company from speaking
with its officers, directors, executive-level employees or internal or external advisors for legitimate business purposes. 
 13.
COOPERATION. In the event of any claim or litigation against the Company and/or Director about which Director has knowledge, Director and Company will cooperate with each other and provide each other such information and documents
as are necessary and reasonably requested by the other, subject to restrictions imposed by federal or state securities laws or court order or injunction. The Company shall cooperate in all respects to ensure that Director has access all available
insurance coverage and shall do nothing to damage Director’s status as an insured, and shall provide all necessary information for Director to make or tender any claim under applicable coverage. 

  
 4 

 14. INSIDER TRADING GUIDELINES. Director agrees to in all respects abide by the
Company’s insider trading guidelines, as such guidelines may be modified from time-to-time. 

15. INDEPENDENT CONTRACTOR. Director’s relationship with the Company shall be that of an independent contractor, and Director will
not be considered an employee of the Company for any purpose. Director will not be eligible for any employee benefits, nor will the Company make deductions from payments made to Director for any taxes or other withholding obligations, which shall be
Director’s responsibility. Director shall not have authority to enter into contracts that bind the Company or create obligations on the part of the Company without the express, prior authorization of the Company. 

16. NOTICES. Any notice required to be given hereunder will be sufficient if in writing and hand delivered or sent by reputable
national overnight delivery carrier, in the case of Director, to his or her address shown on the Company’s records, and in the case of the Company, to the Company’s Chief Executive Officer at 3025 Market Street, Suite 140, Philadelphia, PA
19104 or to such other addresses as either party shall specify to the other. 
 17. INDEMNIFICATION. Director shall have rights to
indemnification and advancement of expenses as provided in the Company’s certificate of incorporation or articles of organization, as applicable; provided, however, that such rights shall not be adversely impacted by any later
amendment to the certificate of incorporation or articles of organization, as applicable. 
 18. WAIVER. No waiver of any provision
of this Agreement will be valid unless the same is in writing and signed by the party against whom such waiver is sought to be enforced. Failure to insist upon strict compliance with any of the terms, covenants or conditions hereof will not be
deemed a waiver of such terms, covenants or conditions, nor will any waiver or relinquishment of any right or power granted hereunder at any particular time be deemed a waiver or relinquishment of such rights or power at any other time or times.

 19. GOVERNING LAW; VENUE. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware,
without regard to that body of law known as choice of law. The parties agree that any litigation arising out of or related to this Agreement or Director’s directorship with the Company will be brought exclusively in any state or federal court
located in Delaware. Each party (a) consents to the personal jurisdiction of said courts, (b) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and (c) agrees not to bring any proceeding
arising out of or relating to this Agreement or Director’s directorship with the Company in any other court, unless and until the above-listed courts refuse jurisdiction. 

20. BENEFIT. This Agreement will be binding upon and will inure to the benefit of each of the parties hereto, and to their respective
heirs, representatives, successors and permitted assigns. Company may assign this Agreement to any affiliate or related entity, or as part of a merger, sale of assets or other transaction. Director may not assign any of his or her rights or delegate
any of his or her duties under this Agreement. 
 21. ENTIRE AGREEMENT. This Agreement contains the entire agreement and
understanding by and between the Company and Director with respect to the terms described herein, and any representations, promises, agreements or understandings, written or oral, not herein contained will be of no force or effect. No change or
modification hereof will be valid or binding unless the same is in writing and signed by the parties hereto. 
 22. CAPTIONS; RULE OF
CONSTRUCTION. The captions in this Agreement are for convenience only and in no way define, bind or describe the scope or intent of this Agreement. The terms 

  
 5 

 
and provisions of this Agreement will not be construed against the drafter or drafters hereof. All parties hereto agree that the language of this Agreement will be construed as a whole according
to its fair meaning and not strictly for or against any of the parties hereto. 
 23. COUNTERPARTS. This Agreement may be
executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same agreement. Facsimile or PDF reproductions of original signatures will be deemed binding for the purpose of the
execution of this Agreement. 
 24. SEVERABILITY. Each provision of this Agreement is severable from every other provision of this
Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable will not affect the validity or enforceability of any other provision. Any provision of this Agreement held invalid
or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 

[signature page follows] 

  
 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective
Date. 
  

									
	DIRECTOR:	 		 	CONTEXT THERAPEUTICS LLC:
					
	By:	 	
                 
	 	            	 	By:	 	  

	Name:	 	
                 
	 		 	Name:	 	Martin Lehr
		 		 		 	Title:	 	Chief Executive Officer

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]